Health & Wellness Today New York: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.

Press releases published on July 7, 2026

Jul. 7, 2026

Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization

Indeterminate GlobeNewswire

Jul. 7, 2026

CoRegen, Inc. Receives FDA Clearance to Advance CRG-150 into Phase 1/2a Clinical Trials, Pioneering a New Frontier in Cell Therapy for Multiple Solid Tumor Types

Indeterminate GlobeNewswire

Jul. 7, 2026

Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Indeterminate GlobeNewswire

Jul. 7, 2026

Arnatar Therapeutics Receives China NMPA Clearance to Initiate First-in-Human Study of ART5, a First-in-Class Up-Regulating ASO Designed to Restore Polycystin-1 for the Treatment of ADPKD

Indeterminate GlobeNewswire

Jul. 7, 2026

Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose

Indeterminate GlobeNewswire

Jul. 7, 2026

Ethos Laboratories Announces Exclusive U.S. Launch of CNSDose™, Following Successful MolDX® Technical Assessment

Indeterminate GlobeNewswire

Jul. 7, 2026

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

Indeterminate GlobeNewswire

Jul. 7, 2026

Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit

Indeterminate GlobeNewswire

Jul. 7, 2026

Nuwellis to Showcase Aquadex Therapy at KidneyBee Summit 2026

Indeterminate GlobeNewswire

Jul. 7, 2026

Lumanity Strengthens Climate Commitment with SBTi (Science Based Targets Initiative) Validation for Near-Term Emissions Reduction Targets

Indeterminate GlobeNewswire

Jul. 7, 2026

Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026

Indeterminate GlobeNewswire

Jul. 7, 2026

Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI

Indeterminate GlobeNewswire

Jul. 7, 2026

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Indeterminate GlobeNewswire

Jul. 7, 2026

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Indeterminate GlobeNewswire

Jul. 7, 2026

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

Indeterminate GlobeNewswire

Jul. 7, 2026

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Indeterminate GlobeNewswire

Jul. 7, 2026

Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential

Indeterminate GlobeNewswire

Jul. 7, 2026

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

Indeterminate GlobeNewswire

Jul. 7, 2026

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

Indeterminate GlobeNewswire

Jul. 7, 2026

HMNC Brain Health Announces Publication of Ketabon (KET01) Clinical Trial Results in JAMA Network Open

Indeterminate GlobeNewswire